Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Romiplostim to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of primary ITP according to the American Society of Hematology (ASH) guidelines at least 6 months prior to screening, regardless of splenectomy status~* Subject must be refractory to a prior ITP therapy, having relapsed after at least 1 prior ITP therapy, or ineligible for other ITP therapies; prior therapy includes first-line therapies~* Age ≥ 1 year and \< 18 years at the time of providing informed consent~* The mean of 2 platelet counts taken during the screening period must be ≤ 30 x 10\^9/L with neither count \> 35 x 10\^9/L~* A serum creatinine concentration ≤ 1.5 times the laboratory normal range (for each age category) during the screening period~* Adequate liver function; serum bilirubin ≤ 1.5 times the laboratory normal range during the screening period; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 times the laboratory normal range during the screening period~* Hemoglobin \> 10.0 g/dL during the screening period~* Subject and/or subject's legally acceptable representative has provided informed consent prior to any study-specific procedure; subject has provided assent, where required~Exclusion Criteria:~* Known history of a bone marrow stem cell disorder; any abnormal bone marrow findings other than those typical of ITP must be approved by Amgen before a subject may be enrolled in the study~* Known active or prior malignancy except adequately treated basal cell carcinoma~* Known history of congenital thrombocytopenia~* Known history of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)~* Known history of H. pylori by urea breath test or stool antigen test within 6 months of enrollment or successfully treated with no evidence of infection~* Known history of systemic lupus erythematosus, evans syndrome, or autoimmune neutropenia~* Known history of antiphospholipid antibody syndrome or positive for lupus anticoagulant~* Known history of disseminated intravascular coagulation, hemolytic uremic syndrome, or thrombotic thrombocytopenic purpura~* Previous history of venous thromboembolism or thrombotic events~* Previous use of romiplostim, pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF), Eltrombopag, recombinant human thrombopoietin (rHuTPO) or any platelet producing agent~* Rituximab (for any indication) or 6-mercaptopurine (6-MP) within 14 weeks before the screening visit, or anticipated use during the time of the proposed study~* Splenectomy within 4 weeks of the screening visit~* All hematopoietic growth factors including interleukin-11 (IL-11) (oprelvekin) within 4 weeks before the screening visit~* Alkylating agents within 8 weeks before the screening visit or anticipated use during the time of the proposed study~* Vaccinations known to decrease platelet counts within 8 weeks before the screening visit~* Known hypersensitivity to any recombinant E coli-derived product (eg, Infergen, Neupogen, Somatropin, and Actimmune)~* Other criteria may apply

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Romiplostim (Type: EXPERIMENTAL): Participants received once weekly subcutaneous romiplostim for 24 weeks at a starting dose of 1 µg/kg; weekly dose increases continued in increments of 1 µg/kg/week to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10\^9/L.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received weekly subcutaneous placebo for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).